CCM
CRL icon

Camber Capital Management’s Charles River Laboratories CRL Stock Holding History

Camber Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-500,000
Closed -$98.4M – 42
2022
Q3 		$98.4M Buy
+500,000
New +$108M 3.01% 12

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Camber Capital Management's CRL Position: Q4 2022 in Review

Camber Capital Management sold out of Charles River Laboratories (CRL) in Q4 2022, closing a stake of 500,000 shares — an estimated $98.4M sold.

Camber Capital Management first reported a position in CRL in Q3 2022 and held it in 1 quarter. The position peaked at $98.4M in Q3 2022. 627 funds tracked by Wall St. Rank hold CRL as of Q4 2022.

  • Camber Capital Management reported no remaining Charles River Laboratories position as of Q4 2022 after selling out during the quarter.
  • Camber Capital Management sold 500,000 Charles River Laboratories shares in Q4 2022, an estimated $98.4M.
  • Camber Capital Management first reported a position in Charles River Laboratories in Q3 2022 and held it in 1 quarter.
  • Camber Capital Management's Charles River Laboratories position peaked at $98.4M in Q3 2022.
  • 627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2022.

Based on Camber Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.